QurAlis
Robin Wojcieszek is an accomplished professional with extensive experience in regulatory affairs and drug safety, currently serving as Senior Vice President of Regulatory Affairs and Drug Safety at QurAlis. Previously, Robin held the position of Vice President and Global Head of Safety & Pharmacovigilance at FibroGen, Inc., and served as Vice President of Regulatory Affairs in the US for Lundbeck. Additionally, Robin contributed as Senior Director at Eli Lilly and Company and is a member of The Critical Path Institute - CAMD.
This person is not in any teams
This person is not in any offices
QurAlis
1 followers
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. They are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.